The application of tetracyclineregulated gene expression systems in the validation of novel drug targets in Mycobacterium tuberculosis

Frontiers in Microbiology

Volumn 6, Issue AUG, 2015, Pages

  Evans, Joanna C ^a,b   Mizrahi, Valerie ^a,b  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Drug discovery; Hypomorphs; Mycobacterium tuberculosis; Regulated gene expression; Target validation; Target based whole cell screening

Indexed keywords

TETRACYCLINE; TRIMETHOPRIM;

BACTERIAL METABOLISM; CELL SCREENING; DRUG DESIGN; DRUG TARGETING; GENE EXPRESSION; GENE EXPRESSION SYSTEM; GENE SILENCING; HUMAN; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHENOTYPE; REVIEW;

EID: 84940974566     PISSN: None     EISSN: 1664302X     Source Type: Journal    
DOI: 10.3389/fmicb.2015.00812     Document Type: Review

References (127)

1. Abrahams, G. L., Kumar, A., Savvi, S., Hung, A. W., Wen, S., Abell, C., et al. (2012a). Pathway-selective sensitization of Mycobacterium tuberculosis for target-based whole-cell screening. Chem. Biol. 19, 844-854. doi: 10.1016/j.chembiol.2012.05.020
2. Abrahams, K. A., Cox, J. A., Spivey, V. L., Loman, N. J., Pallen, M. J., Constantinidou, C., et al. (2012b). Identification of novel imidazo[1,2-a]pyridine inhibitors targeting M. tuberculosis QcrB. PLoS ONE 7:e52951. doi: 10.1371/journal.pone.0052951
3. Ahidjo, B. A., Kuhnert, D., Mckenzie, J. L., Machowski, E. E., Gordhan, B. G., Arcus, V., et al. (2011). VapC toxins from Mycobacterium tuberculosis are ribonucleases that differentially inhibit growth and are neutralized by cognate VapB antitoxins. PLoS ONE 6:e21738. doi: 10.1371/journal.pone.0021738
4. Ahmed, W., Menon, S., Godbole, A. A., Karthik, P. V., and Nagaraja, V. (2014). Conditional silencing of topoisomerase I gene of Mycobacterium tuberculosis validates its essentiality for cell survival. FEMS Microbiol. Lett. 353, 116-123. doi: 10.1111/1574-6968.12412
5. Andries, K., Verhasselt, P., Guillemont, J., Gohlmann, H. W., Neefs, J. M., Winkler, H., et al. (2005). A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307, 223-227. doi: 10.1126/science.1106753
6. Barbosa, M. D., Lin, S., Markwalder, J. A., Mills, J. A., Devito, J. A., Teleha, C. A., et al. (2002). Regulated expression of the Escherichia coli lepB gene as a tool for cellular testing of antimicrobial compounds that inhibit signal peptidase I in vitro. Antimicrob. Agents Chemother. 46, 3549-3554. doi: 10.1128/aac.46.11.3549-3554.2002
7. Barry, C. E., Boshoff, H. I., Dartois, V., Dick, T., Ehrt, S., Flynn, J., et al. (2009). The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat. Rev. Microbiol. 7, 845-855. doi: 10.1038/nrmicro2236
8. Begley, T. P., Kinsland, C., and Strauss, E. (2001). The biosynthesis of coenzyme A in bacteria. Vitam. Horm. 61, 157-171. doi: 10.1016/S0083-6729(01)61005-7
9. Berens, C., and Hillen, W. (2003). Gene regulation by tetracyclines. Eur. J. Biochem. 270, 3109-3121. doi: 10.1046/j.1432-1033.2003.03694.x
10. Bertram, R., and Hillen, W. (2008). The application of Tet repressor in prokaryotic gene regulation and expression. Microb. Biotechnol. 1, 2-16. doi: 10.1111/j.1751-7915.2007.00001.x
11. Beste, D. J., Espasa, M., Bonde, B., Kierzek, A. M., Stewart, G. R., and Mcfadden, J. (2009). The genetic requirements for fast and slow growth in mycobacteria. PLoS ONE 4:e5349. doi: 10.1371/journal.pone.0005349
12. 13C-flux spectral analysis of host-pathogen metabolism reveals a mixed diet for intracellular Mycobacterium tuberculosis. Chem. Biol. 20, 1012-1021. doi: 10.1016/j.chembiol.2013.06.012
13. Bhat, J., Narayan, A., Venkatraman, J., and Chatterji, M. (2013). LC-MS based assay to measure intracellular compound levels in Mycobacterium smegmatis: linking compound levels to cellular potency. J. Microbiol. Methods 94, 152-158. doi: 10.1016/j.mimet.2013.05.010
14. Bjorkelid, C., Bergfors, T., Raichurkar, A. K., Mukherjee, K., Malolanarasimhan, K., Bandodkar, B., et al. (2013). Structural and biochemical characterization of compounds inhibiting Mycobacterium tuberculosis pantothenate kinase. J. Biol. Chem. 288, 18260-18270. doi: 10.1074/jbc.M113.476473
15. Blanco, D., Perez-Herran, E., Cacho, M., Ballell, L., Castro, J., Gonzalez Del Rio, R., et al. (2015). Mycobacterium tuberculosis gyrase inhibitors (MGI) as a new class of antitubercular drugs. Antimicrob. Agents Chemother. 59, 1868-1875. doi: 10.1128/AAC.03913-14
16. Bloch, H., and Segal, W. (1956). Biochemical differentiation of Mycobacterium tuberculosis grown in vivo and in vitro. J. Bacteriol. 72, 132-141.
17. Blokpoel, M. C., Murphy, H. N., O'toole, R., Wiles, S., Runn, E. S., Stewart, G. R., et al. (2005). Tetracycline-inducible gene regulation in mycobacteria. Nucleic Acids Res. 33, e22. doi: 10.1093/nar/gni023
18. Blumenthal, A., Trujillo, C., Ehrt, S., and Schnappinger, D. (2010). Simultaneous analysis of multiple Mycobacterium tuberculosis knockdown mutants in vitro and in vivo. PLoS ONE 5:e15667. doi: 10.1371/journal.pone.0015667
19. Boldrin, F., Casonato, S., Dainese, E., Sala, C., Dhar, N., Palu, G., et al. (2010). Development of a repressible mycobacterial promoter system based on two transcriptional repressors. Nucleic Acids Res. 38, e134. doi: 10.1093/nar/gkq235
20. Boldrin, F., Ventura, M., Degiacomi, G., Ravishankar, S., Sala, C., Svetlikova, Z., et al. (2014). The phosphatidyl-myo-inositol mannosyltransferase PimA is essential for Mycobacterium tuberculosis growth in vitro and in vivo. J. Bacteriol. 196, 3441-3451. doi: 10.1128/JB.01346-13
21. Boshoff, H. I., Xu, X., Tahlan, K., Dowd, C. S., Pethe, K., Camacho, L. R., et al. (2008). Biosynthesis and recycling of nicotinamide cofactors in Mycobacterium tuberculosis. J. Biol. Chem. 283, 19329-19341. doi: 10.1074/jbc.M800694200
22. Brecik, M., Centarova, I., Mukherjee, R., Kolly, G. S., Huszar, S., Bobovska, A., et al. (2015). DprE1 is a vulnerable tuberculosis drug target due to its cell wall localization. ACS Chem. Biol. 10, 1631-1636. doi: 10.1021/acschembio.5b00237
23. Brown, A. C., and Parish, T. (2006). Instability of the acetamide-inducible expression vector pJAM2 in Mycobacterium tuberculosis. Plasmid 55, 81-86. doi: 10.1016/j.plasmid.2005.06.005
24. Carroll, P., Faray-Kele, M. C., and Parish, T. (2011). Identifying vulnerable pathways in Mycobacterium tuberculosis by using a knockdown approach. Appl. Environ. Microbiol. 77, 5040-5043. doi: 10.1128/AEM.02880-10
25. Carroll, P., Muttucumaru, D. G., and Parish, T. (2005). Use of a tetracycline-inducible system for conditional expression in Mycobacterium tuberculosis and Mycobacterium smegmatis. Appl. Environ. Microbiol. 71, 3077-3084. doi: 10.1128/AEM.71.6.3077-3084.2005
26. Choudhary, E., Thakur, P., Pareek, M., and Agarwal, N. (2015). Gene silencing by CRISPR interference in mycobacteria. Nat. Commun. 6, 6267. doi: 10.1038/ncomms7267
27. Christophe, T., Jackson, M., Jeon, H. K., Fenistein, D., Contreras-Dominguez, M., Kim, J., et al. (2009). High content screening identifies decaprenyl-phosphoribose 2' epimerase as a target for intracellular antimycobacterial inhibitors. PLoS Pathog. 5:e1000645. doi: 10.1371/journal.ppat.1000645
28. Chuang, Y. M., Bandyopadhyay, N., Rifat, D., Rubin, H., Bader, J. S., and Karakousis, P. C. (2015). Deficiency of the novel exopolyphosphatase Rv1026/PPX2 leads to metabolic downshift and altered cell wall permeability in Mycobacterium tuberculosis. MBio 6:e02428. doi: 10.1128/mBio.02428-14
29. Ciulli, A., Scott, D. E., Ando, M., Reyes, F., Saldanha, S. A., Tuck, K. L., et al. (2008). Inhibition of Mycobacterium tuberculosis pantothenate synthetase by analogues of the reaction intermediate. Chembiochem 9, 2606-2611. doi: 10.1002/cbic.200800437
30. Cohen, J. (2013). Infectious disease. Science 339, 130. doi: 10.1126/science.339.6116.130
31. Cole, S. T., and Riccardi, G. (2011). New tuberculosis drugs on the horizon. Curr. Opin. Microbiol. 14, 570-576. doi: 10.1016/j.mib.2011.07.022
32. Das, S., Kumar, P., Bhor, V., Surolia, A., and Vijayan, M. (2006). Invariance and variability in bacterial PanK: a study based on the crystal structure of Mycobacterium tuberculosis PanK. Acta Crystallogr. D Biol. Crystallogr. 62, 628-638. doi: 10.1107/S0907444906012728
33. Daugelat, S., Kowall, J., Mattow, J., Bumann, D., Winter, R., Hurwitz, R., et al. (2003). The RD1 proteins of Mycobacterium tuberculosis: expression in Mycobacterium smegmatis and biochemical characterization. Microbes Infect. 5, 1082-1095. doi: 10.1016/s1286-4579(03)00205-3
34. Dawson, R., Diacon, A. H., Everitt, D., Van Niekerk, C., Donald, P. R., Burger, D. A., et al. (2015). Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis. Lancet 385, 1738-1747. doi: 10.1016/s0140-6736(14)62002-x
35. DeVito, J. A., Mills, J. A., Liu, V. G., Agarwal, A., Sizemore, C. F., Yao, Z., et al. (2002). An array of target-specific screening strains for antibacterial discovery. Nat. Biotechnol. 20, 478-483. doi: 10.1038/nbt0502-478
36. Drlica, K., and Zhao, X. (1997). DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol. Mol. Biol. Rev. 61, 377-392.
37. Dziadek, J. (2003). Conditional expression of Mycobacterium smegmatis ftsZ, an essential cell division gene. Microbiology 149, 1593-1603. doi: 10.1099/mic.0.26023-0
38. Ehrt, S., Guo, X. V., Hickey, C. M., Ryou, M., Monteleone, M., Riley, L. W., et al. (2005). Controlling gene expression in mycobacteria with anhydrotetracycline and Tet repressor. Nucleic Acids Res. 33, e21. doi: 10.1093/nar/gni013
39. Ehrt, S., and Schnappinger, D. (2006). Controlling gene expression in mycobacteria. Future Microbiol. 1, 177-184. doi: 10.2217/17460913.1.2.177
40. Forti, F., Crosta, A., and Ghisotti, D. (2009). Pristinamycin-inducible gene regulation in mycobacteria. J. Biotechnol. 140, 270-277. doi: 10.1016/j.jbiotec.2009.02.001
41. Gandotra, S., Schnappinger, D., Monteleone, M., Hillen, W., and Ehrt, S. (2007). In vivo gene silencing identifies the Mycobacterium tuberculosis proteasome as essential for the bacteria to persist in mice. Nat. Med. 13, 1515-1520. doi: 10.1038/nm1683
42. Gee, C. L., Papavinasasundaram, K. G., Blair, S. R., Baer, C. E., Falick, A. M., King, D. S., et al. (2012). A phosphorylated pseudokinase complex controls cell wall synthesis in mycobacteria. Sci. Signal. 5:ra7. doi: 10.1126/scisignal.2002525
43. Gill, W. P., Harik, N. S., Whiddon, M. R., Liao, R. P., Mittler, J. E., and Sherman, D. R. (2009). A replication clock for Mycobacterium tuberculosis. Nat. Med. 15, 211-214. doi: 10.1038/nm.1915
44. Gler, M. T., Skripconoka, V., Sanchez-Garavito, E., Xiao, H., Cabrera-Rivero, J. L., Vargas-Vasquez, D. E., et al. (2012). Delamanid for multidrug-resistant pulmonary tuberculosis. N. Engl. J. Med. 366, 2151-2160. doi: 10.1056/NEJMoa1112433
45. Gomez, J. E., and Bishai, W. R. (2000). whmD is an essential mycobacterial gene required for proper septation and cell division. Proc. Natl. Acad. Sci. U.S.A. 97, 8554-8559. doi: 10.1073/pnas.140225297
46. Greendyke, R., Rajagopalan, M., Parish, T., and Madiraju, M. V. (2002). Conditional expression of Mycobacterium smegmatis dnaA, an essential DNA replication gene. Microbiology 148, 3887-3900.
47. Griffin, J. E., Gawronski, J. D., Dejesus, M. A., Ioerger, T. R., Akerley, B. J., and Sassetti, C. M. (2011). High-resolution phenotypic profiling defines genes essential for mycobacterial growth and cholesterol catabolism. PLoS Pathog. 7:e1002251. doi: 10.1371/journal.ppat.1002251
48. Griffin, J. E., Pandey, A. K., Gilmore, S. A., Mizrahi, V., Mckinney, J. D., Bertozzi, C. R., et al. (2012). Cholesterol catabolism by Mycobacterium tuberculosis requires transcriptional and metabolic adaptations. Chem. Biol. 19, 218-227. doi: 10.1016/j.chembiol.2011.12.016
49. Griffith, K. L., and Grossman, A. D. (2008). Inducible protein degradation in Bacillus subtilis using heterologous peptide tags and adaptor proteins to target substrates to the protease ClpXP. Mol. Microbiol. 70, 1012-1025. doi: 10.1111/j.1365-2958.2008.06467.x
50. Guo, X. V., Monteleone, M., Klotzsche, M., Kamionka, A., Hillen, W., Braunstein, M., et al. (2007). Silencing Mycobacterium smegmatis by using tetracycline repressors. J. Bacteriol. 189, 4614-4623. doi: 10.1128/JB.00216-7
51. Hartkoorn, R. C., Sala, C., Neres, J., Pojer, F., Magnet, S., Mukherjee, R., et al. (2012). Towards a new tuberculosis drug: pyridomycin-nature's isoniazid. EMBO Mol. Med. 4, 1032-1042. doi: 10.1002/emmm.201201689
52. Hung, A. W., Silvestre, H. L., Wen, S., Ciulli, A., Blundell, T. L., and Abell, C. (2009). Application of fragment growing and fragment linking to the discovery of inhibitors of Mycobacterium tuberculosis pantothenate synthetase. Angew. Chem. Int. Ed. Engl. 48, 8452-8456. doi: 10.1002/anie.200903821
53. Kim, J. H., O'Brien, K. M., Sharma, R., Boshoff, H. I., Rehren, G., Chakraborty, S., et al. (2013). A genetic strategy to identify targets for the development of drugs that prevent bacterial persistence. Proc. Natl. Acad. Sci. U.S.A. 110, 19095-19100. doi: 10.1073/pnas.1315860110
54. Kim, J. H., Wei, J. R., Wallach, J. B., Robbins, R. S., Rubin, E. J., and Schnappinger, D. (2011). Protein inactivation in mycobacteria by controlled proteolysis and its application to deplete the beta subunit of RNA polymerase. Nucleic Acids Res. 39, 2210-2220. doi: 10.1093/nar/gkq1149
55. Kitahara, T., Hotta, K., Yoshida, M., and Okami, Y. (1975). Biological studies of amiclenomycin. J. Antibiot. (Tokyo) 28, 215-221. doi: 10.7164/antibiotics.28.215
56. Kjellsson, M. C., Via, L. E., Goh, A., Weiner, D., Low, K. M., Kern, S., et al. (2012). Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions. Antimicrob. Agents Chemother. 56, 446-457. doi: 10.1128/AAC.05208-11
57. Klotzsche, M., Ehrt, S., and Schnappinger, D. (2009). Improved tetracycline repressors for gene silencing in mycobacteria. Nucleic Acids Res. 37, 1778-1788. doi: 10.1093/nar/gkp015
58. Kohanski, M. A., Dwyer, D. J., Wierzbowski, J., Cottarel, G., and Collins, J. J. (2008). Mistranslation of membrane proteins and two-component system activation trigger antibiotic-mediated cell death. Cell 135, 679-690. doi: 10.1016/j.cell.2008.09.038
59. Kolly, G. S., Boldrin, F., Sala, C., Dhar, N., Hartkoorn, R. C., Ventura, M., et al. (2014a). Assessing the essentiality of the decaprenyl-phospho-d-arabinofuranose pathway in Mycobacterium tuberculosis using conditional mutants. Mol. Microbiol. 92, 194-211. doi: 10.1111/mmi.12546
60. Kolly, G. S., Sala, C., Vocat, A., and Cole, S. T. (2014b). Assessing essentiality of transketolase in Mycobacterium tuberculosis using an inducible protein degradation system. FEMS Microbiol. Lett. 358, 30-35. doi: 10.1111/1574-6968.12536
61. Krieger, I. V., Freundlich, J. S., Gawandi, V. B., Roberts, J. P., Gawandi, V. B., Sun, Q., et al. (2012). Structure-guided discovery of phenyl-diketo acids as potent inhibitors of M. tuberculosis malate synthase. Chem. Biol. 19, 1556-1567. doi: 10.1016/j.chembiol.2012.09.018
62. Kumar, A., Casey, A., Odingo, J., Kesicki, E. A., Abrahams, G., Vieth, M., et al. (2013). A high-throughput screen against pantothenate synthetase (PanC) identifies 3-biphenyl-4-cyanopyrrole-2-carboxylic acids as a new class of inhibitor with activity against Mycobacterium tuberculosis. PLoS ONE 8:e72786. doi: 10.1371/journal.pone.0072786
63. Kumar, A., Zhang, M., Zhu, L., Liao, R. P., Mutai, C., Hafsat, S., et al. (2012). High-throughput screening and sensitized bacteria identify an M. tuberculosis dihydrofolate reductase inhibitor with whole cell activity. PLoS ONE 7:e39961. doi: 10.1371/journal.pone.0039961
64. Lakshminarayana, S. B., Huat, T. B., Ho, P. C., Manjunatha, U. H., Dartois, V., Dick, T., et al. (2015). Comprehensive physicochemical, pharmacokinetic and activity profiling of anti-TB agents. J. Antimicrob. Chemother. 70, 857-867. doi: 10.1093/jac/dku457
65. Leblanc, C., Prudhomme, T., Tabouret, G., Ray, A., Burbaud, S., Cabantous, S., et al. (2012). 4'-Phosphopantetheinyl transferase PptT, a new drug target required for Mycobacterium tuberculosis growth and persistence in vivo. PLoS Pathog. 8:e1003097. doi: 10.1371/journal.ppat.1003097
66. Lederer, T., Kintrup, M., Takahashi, M., Sum, P. E., Ellestad, G. A., and Hillen, W. (1996). Tetracycline analogs affecting binding to Tn10-Encoded Tet repressor trigger the same mechanism of induction. Biochemistry 35, 7439-7446. doi: 10.1021/bi952683e
67. Lee, H. N., Lee, N. O., Han, S. J., Ko, I. J., and Oh, J. I. (2014). Regulation of the ahpC gene encoding alkyl hydroperoxide reductase in Mycobacterium smegmatis. PLoS ONE 9:e111680. doi: 10.1371/journal.pone.0111680
68. Levchenko, I., Seidel, M., Sauer, R. T., and Baker, T. A. (2000). A specificity-enhancing factor for the ClpXP degradation machine. Science 289, 2354-2356. doi: 10.1126/science.289.5488.2354
69. Ling, L. L., Schneider, T., Peoples, A. J., Spoering, A. L., Engels, I., Conlon, B. P., et al. (2015). A new antibiotic kills pathogens without detectable resistance. Nature 517, 455-459. doi: 10.1038/nature14098
70. Lu, H., and Tonge, P. J. (2010). Drug-target residence time: critical information for lead optimization. Curr. Opin. Chem. Biol. 14, 467-474. doi: 10.1016/j.cbpa.2010.06.176
71. Magnet, S., Hartkoorn, R. C., Szekely, R., Pato, J., Triccas, J. A., Schneider, P., et al. (2010). Leads for antitubercular compounds from kinase inhibitor library screens. Tuberculosis (Edinb.) 90, 354-360. doi: 10.1016/j.tube.2010.09.001
72. Mak, P. A., Rao, S. P., Ping Tan, M., Lin, X., Chyba, J., Tay, J., et al. (2012). A high-throughput screen to identify inhibitors of ATP homeostasis in non-replicating Mycobacterium tuberculosis. ACS Chem. Biol. 7, 1190-1197. doi: 10.1021/cb2004884
73. Makarov, V., Manina, G., Mikusova, K., Mollmann, U., Ryabova, O., Saint-Joanis, B., et al. (2009). Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. Science 324, 801-804. doi: 10.1126/science.1171583
74. Manjunatha, U. H., Rao, S. P. S., Kondreddi, R. R., Noble, C. G., Camacho, L. R., Tan, B. H., et al. (2015). Direct inhibitors of InhA are active against Mycobacterium tuberculosis. Sci. Transl. Med. 7, 269ra263. doi: 10.1126/scitranslmed.3010597
75. Marrero, J., Rhee, K. Y., Schnappinger, D., Pethe, K., and Ehrt, S. (2010). Gluconeogenic carbon flow of tricarboxylic acid cycle intermediates is critical for Mycobacterium tuberculosis to establish and maintain infection. Proc. Natl. Acad. Sci. U.S.A. 107, 9819-9824. doi: 10.1073/pnas.1000715107
76. Matsumoto, M., Hashizume, H., Tomishige, T., Kawasaki, M., Tsubouchi, H., Sasaki, H., et al. (2006). OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PloS Med. 3:e466. doi: 10.1371/journal.pmed.0030466
77. Moolman, W. J., De Villiers, M., and Strauss, E. (2014). Recent advances in targeting coenzyme A biosynthesis and utilization for antimicrobial drug development. Biochem. Soc. Trans. 42, 1080-1086. doi: 10.1042/BST20140131
78. Moullan, N., Mouchiroud, L., Wang, X., Ryu, D., Williams, E. G., Mottis, A., et al. (2015). Tetracyclines disturb mitochondrial function across eukaryotic models: a call for caution in biomedical research. Cell Rep. 10, 1681-1691. doi: 10.1016/j.celrep.2015.02.034
79. Munoz-Elias, E. J., and McKinney, J. D. (2005). Mycobacterium tuberculosis isocitrate lyases 1 and 2 are jointly required for in vivo growth and virulence. Nat. Med. 11, 638-644. doi: 10.1038/nm1252
80. Murima, P., Mckinney, J. D., and Pethe, K. (2014). Targeting bacterial central metabolism for drug development. Chem. Biol. 21, 1423-1432. doi: 10.1016/j.chembiol.2014.08.020
81. Ojha, A. K., Mukherjee, T. K., and Chatterji, D. (2000). High intracellular level of guanosine tetraphosphate in Mycobacterium smegmatis changes the morphology of the bacterium. Infect. Immun. 68, 4084-4091. doi: 10.1128/IAI.68.7.4084-4091.2000
82. Ollinger, J., O'Malley, T., Ahn, J., Odingo, J., and Parish, T. (2012a). Inhibition of the sole type I signal peptidase of Mycobacterium tuberculosis is bactericidal under replicating and nonreplicating conditions. J. Bacteriol. 194, 2614-2619. doi: 10.1128/JB.00224-12
83. Ollinger, J., O'Malley, T., Kesicki, E. A., Odingo, J., and Parish, T. (2012b). Validation of the essential ClpP protease in Mycobacterium tuberculosis as a novel drug target. J. Bacteriol. 194, 663-668. doi: 10.1128/JB.06142-11
84. Palmer, A. C., and Kishony, R. (2014). Opposing effects of target overexpression reveal drug mechanisms. Nat. Commun. 5, 4296. doi: 10.1038/ncomms5296
85. Pandey, A. K., Raman, S., Proff, R., Joshi, S., Kang, C. M., Rubin, E. J., et al. (2009). Nitrile-inducible gene expression in mycobacteria. Tuberculosis (Edinb.) 89, 12-16. doi: 10.1016/j.tube.2008.07.007
86. Parish, T., Mahenthiralingam, E., Draper, P., Davis, E. O., and Colston, M. J. (1997). Regulation of the inducible acetamidase gene of Mycobacterium smegmatis. Microbiology 143(Pt 7), 2267-2276. doi: 10.1099/00221287-143-7-2267
87. Parish, T., Turner, J., and Stoker, N. G. (2001). amiA is a negative regulator of acetamidase expression in Mycobacterium smegmatis. BMC Microbiol. 1:19. doi: 10.1186/1471-2180-1-19
88. Park, S. W., Casalena, D. E., Wilson, D. J., Dai, R., Nag, P. P., Liu, F., et al. (2015). Target-Based Identification of Whole-Cell Active Inhibitors of Biotin Biosynthesis in Mycobacterium tuberculosis. Chem. Biol. 22, 76-86. doi: 10.1016/j.chembiol.2014.11.012
89. Payne, D. J., Gwynn, M. N., Holmes, D. J., and Pompliano, D. L. (2007). Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov. 6, 29-40. doi: 10.1038/nrd2201
90. Pethe, K., Bifani, P., Jang, J., Kang, S., Park, S., Ahn, S., et al. (2013). Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. Nat. Med. 19, 1157-1160. doi: 10.1038/nm.3262
91. Pethe, K., Sequeira, P. C., Agarwalla, S., Rhee, K., Kuhen, K., Phong, W. Y., et al. (2010). A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy. Nat. Commun. 1, 57. doi: 10.1038/ncomms1060
92. Petrella, S., Cambau, E., Chauffour, A., Andries, K., Jarlier, V., and Sougakoff, W. (2006). Genetic basis for natural and acquired resistance to the diarylquinoline R207910 in mycobacteria. Antimicrob. Agents Chemother. 50, 2853-2856. doi: 10.1128/AAC.00244-6
93. Phillips, J. W., Goetz, M. A., Smith, S. K., Zink, D. L., Polishook, J., Onishi, R., et al. (2011). Discovery of kibdelomycin, a potent new class of bacterial type II topoisomerase inhibitor by chemical-genetic profiling in Staphylococcus aureus. Chem. Biol. 18, 955-965. doi: 10.1016/j.chembiol.2011.06.011
94. Preiss, L., Langer, J. D., Yildiz, O., Eckhardt-Strelau, L., Guillemont, J. E. G., Koul, A., et al. (2015). Structure of the mycobacterial ATP synthase Fo rotor ring in complex with the anti-TB drug bedaquiline. Sci. Adv. 1:e1500106. doi: 10.1126/sciadv.1500106
95. Puckett, S., Trujillo, C., Eoh, H., Marrero, J., Spencer, J., Jackson, M., et al. (2014). Inactivation of fructose-1,6-bisphosphate aldolase prevents optimal co-catabolism of glycolytic and gluconeogenic carbon substrates in Mycobacterium tuberculosis. PLoS Pathog. 10:e1004144. doi: 10.1371/journal.ppat.1004144
96. Raju, R. M., Unnikrishnan, M., Rubin, D. H., Krishnamoorthy, V., Kandror, O., Akopian, T. N., et al. (2012). Mycobacterium tuberculosis ClpP1 and ClpP2 function together in protein degradation and are required for viability in vitro and during infection. PLoS Pathog. 8:e1002511. doi: 10.1371/journal.ppat.1002511
97. Reddy, B. K., Landge, S., Ravishankar, S., Patil, V., Shinde, V., Tantry, S., et al. (2014). Assessment of Mycobacterium tuberculosis pantothenate kinase vulnerability through target knockdown and mechanistically diverse inhibitors. Antimicrob. Agents Chemother. 58, 3312-3326. doi: 10.1128/AAC.00140-14
98. Rengarajan, J., Bloom, B. R., and Rubin, E. J. (2005). Genome-wide requirements for Mycobacterium tuberculosis adaptation and survival in macrophages. Proc. Natl. Acad. Sci. U.S.A. 102, 8327-8332. doi: 10.1073/pnas.0503272102
99. Rittershaus, E. S., Baek, S. H., and Sassetti, C. M. (2013). The normalcy of dormancy: common themes in microbial quiescence. Cell Host Microbe 13, 643-651. doi: 10.1016/j.chom.2013.05.012
100. Rodionova, I. A., Schuster, B. M., Guinn, K. M., Sorci, L., Scott, D. A., Li, X., et al. (2014). Metabolic and bactericidal effects of targeted suppression of NadD and NadE enzymes in mycobacteria. MBio 5:e747-13. doi: 10.1128/mBio.00747-13
101. Sandmark, J., Mann, S., Marquet, A., and Schneider, G. (2002). Structural basis for the inhibition of the biosynthesis of biotin by the antibiotic amiclenomycin. J. Biol. Chem. 277, 43352-43358. doi: 10.1074/jbc.M207239200
102. Sassetti, C. M., Boyd, D. H., and Rubin, E. J. (2003). Genes required for mycobacterial growth defined by high density mutagenesis. Mol. Microbiol. 48, 77-84. doi: 10.1046/j.1365-2958.2003.03425.x
103. Sassetti, C. M., and Rubin, E. J. (2003). Genetic requirements for mycobacterial survival during infection. Proc. Natl. Acad. Sci. U.S.A. 100, 12989-12994. doi: 10.1073/pnas.2134250100
104. Schnappinger, D., and Ehrt, S. (2014). Regulated expression systems for mycobacteria and their applications. Microbiol. Spectr. 2, 03. doi: 10.1128/microbiolspec.MGM2-0018-2013
105. Schnappinger, D., Ehrt, S., Voskuil, M. I., Liu, Y., Mangan, J. A., Monahan, I. M., et al. (2003). Transcriptional adaptation of Mycobacterium tuberculosis within macrophages: Insights into the phagosomal environment. J. Exp. Med. 198, 693-704. doi: 10.1084/jem.20030846
106. Shi, C., Geders, T. W., Park, S. W., Wilson, D. J., Boshoff, H. I., Abayomi, O., et al. (2011). Mechanism-based inactivation by aromatization of the transaminase BioA involved in biotin biosynthesis in Mycobacterium tuberculosis. J. Am. Chem. Soc. 133, 18194-18201. doi: 10.1021/ja204036t
107. Singh, V., Brecik, M., Mukherjee, R., Evans, J. C., Svetlikova, Z., Blasko, J., et al. (2015). The complex mechanism of antimycobacterial action of 5-Fluorouracil. Chem. Biol. 22, 63-75. doi: 10.1016/j.chembiol.2014.11.006
108. Spry, C., Kirk, K., and Saliba, K. J. (2008). Coenzyme A biosynthesis: an antimicrobial drug target. FEMS Microbiol. Rev. 32, 56-106. doi: 10.1111/j.1574-6976.2007.00093.x
109. Srivastava, D. B., Leon, K., Osmundson, J., Garner, A. L., Weiss, L. A., Westblade, L. F., et al. (2013). Structure and function of CarD, an essential mycobacterial transcription factor. Proc. Natl. Acad. Sci. U.S.A. 110, 12619-12624. doi: 10.1073/pnas.1308270110
110. Stallings, C. L., Stephanou, N. C., Chu, L., Hochschild, A., Nickels, B. E., and Glickman, M. S. (2009). CarD is an essential regulator of rRNA transcription required for Mycobacterium tuberculosis persistence. Cell 138, 146-159. doi: 10.1016/j.cell.2009.04.041
111. Stanley, S. A., Grant, S. S., Kawate, T., Iwase, N., Shimizu, M., Wivagg, C., et al. (2012). Identification of novel inhibitors of M. tuberculosis growth using whole cell based high-throughput screening. ACS Chem. Biol. 7, 1377-1384. doi: 10.1021/cb300151m
112. Stover, C. K., Warrener, P., Vandevanter, D. R., Sherman, D. R., Arain, T. M., Langhorne, M. H., et al. (2000). A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 405, 962-966. doi: 10.1038/35016103
113. Trauner, A., Lougheed, K. E., Bennett, M. H., Hingley-Wilson, S. M., and Williams, H. D. (2012). The dormancy regulator DosR controls ribosome stability in hypoxic mycobacteria. J. Biol. Chem. 287, 24053-24063. doi: 10.1074/jbc.M112.364851
114. Triccas, J. A., Parish, T., Britton, W. J., and Gicquel, B. (1998). An inducible expression system permitting the efficient purification of a recombinant antigen from Mycobacterium smegmatis. FEMS Microbiol. Lett. 167, 151-156. doi: 10.1111/j.1574-6968.1998.tb13221.x
115. Trujillo, C., Blumenthal, A., Marrero, J., Rhee, K. Y., Schnappinger, D., and Ehrt, S. (2014). Triosephosphate isomerase is dispensable in vitro yet essential for Mycobacterium tuberculosis to establish infection. MBio 5:e00085. doi: 10.1128/mBio.00085-14
116. Ventura, M., Rieck, B., Boldrin, F., Degiacomi, G., Bellinzoni, M., Barilone, N., et al. (2013). GarA is an essential regulator of metabolism in Mycobacterium tuberculosis. Mol. Microbiol. 90, 356-366. doi: 10.1111/mmi.12368
117. Wang, F., Sambandan, D., Halder, R., Wang, J., Batt, S. M., Weinrick, B., et al. (2013). Identification of a small molecule with activity against drug-resistant and persistent tuberculosis. Proc. Natl. Acad. Sci. U.S.A. 110, E2510-7. doi: 10.1073/pnas.1309171110
118. Wang, J., Soisson, S. M., Young, K., Shoop, W., Kodali, S., Galgoci, A., et al. (2006). Platensimycin is a selective FabF inhibitor with potent antibiotic properties. Nature 441, 358-361. doi: 10.1038/nature04784
119. Wei, J. R., Krishnamoorthy, V., Murphy, K., Kim, J. H., Schnappinger, D., Alber, T., et al. (2011). Depletion of antibiotic targets has widely varying effects on growth. Proc. Natl. Acad. Sci. U.S.A. 108, 4176-4181. doi: 10.1073/pnas.1018301108
120. Weiss, L. A., and Stallings, C. L. (2013). Essential roles for Mycobacterium tuberculosis Rel beyond the production of (p)ppGpp. J. Bacteriol. 195, 5629-5638. doi: 10.1128/JB.00759-13
121. WHO. (2014). Global Tuberculosis Report 2014. Geneva: World Health Organisation.
122. Willand, N., Dirie, B., Carette, X., Bifani, P., Singhal, A., Desroses, M., et al. (2009). Synthetic EthR inhibitors boost antituberculous activity of ethionamide. Nat. Med. 15, 537-544. doi: 10.1038/nm.1950
123. Wolucka, B. A. (2008). Biosynthesis of D-arabinose in mycobacteria-a novel bacterial pathway with implications for antimycobacterial therapy. FEBS J. 275, 2691-2711. doi: 10.1111/j.1742-4658.2008.06395.x
124. Woong Park, S., Klotzsche, M., Wilson, D. J., Boshoff, H. I., Eoh, H., Manjunatha, U., et al. (2011). Evaluating the sensitivity of Mycobacterium tuberculosis to biotin deprivation using regulated gene expression. PLoS Pathog. 7:e1002264. doi: 10.1371/journal.ppat.1002264
125. Xu, Z., Yin, W., Martinelli, L. K., Evans, J., Chen, J., Yu, Y., et al. (2014). Reaction intermediate analogues as bisubstrate inhibitors of pantothenate synthetase. Bioorg. Med. Chem. 22, 1726-1735. doi: 10.1016/j.bmc.2014.01.017
126. Young, K., Jayasuriya, H., Ondeyka, J. G., Herath, K., Zhang, C., Kodali, S., et al. (2006). Discovery of FabH/FabF inhibitors from natural products. Antimicrob. Agents Chemother. 50, 519-526. doi: 10.1128/AAC.50.2.519-526.2006
127. Zumla, A., Nahid, P., and Cole, S. T. (2013). Advances in the development of new tuberculosis drugs and treatment regimens. Nat. Rev. Drug Discov. 12, 388-404. doi: 10.1038/nrd4001